Granulocyte colony-stimulating factor (G-CSF) is a well known regulator of granulopoiesis, but the role of endogenous G-CSF in inflammatory joint disease has not been explored. We studied the response of G-CSF-deficient mice in experimental models of joint inflammation. We show that G-CSF deficiency protects mice from acute and chronic arthritis. Reduced severity was associated with blunted mobilization of granulocytic cells from the bone marrow and less cellular infiltrate and cellular activation in inflamed joints. We also demonstrate that G-CSF blockade in established collageninduced arthritis in WT mice markedly reduces disease manifestations and is as effective as tumor necrosis factor blockade. Our results reveal a critical role for G-CSF in driving joint inflammation and highlight G-CSF as a potential therapeutic target in inflammatory joint diseases, such as rheumatoid arthritis.
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R
heumatoid arthritis (RA) is a chronic autoimmune disease of unknown etiology in which synovial joints bear the brunt of an inflammatory process. The preclinical stages of RA are still poorly understood, but, in established RA, there is sustained local overproduction of proinflammatory cytokines, with perhaps a central role for tumor necrosis factor (TNF) (1) .
Granulocyte colony-stimulating factor (G-CSF) is the major regulator of granulocyte production. G-CSF is produced by bone marrow stromal cells, endothelial cells, macrophages, and fibroblasts, and production is induced by inflammatory stimuli. G-CSF acts through the G-CSF receptor (G-CSFR), which is expressed on early myeloid progenitors, mature neutrophils, and monocytes͞macrophages, as well as endothelial cells (2) . Recently, G-CSFRs have also been described on human T and B lymphocytes (3, 4) . Mice deficient in G-CSF or the G-CSFR exhibit marked neutropenia, demonstrating the importance of G-CSF in steady-state granulopoiesis (5, 6) . However, G-CSF seems to be dispensable for emergency granulopoiesis (7) . G-CSF increases the production and release of neutrophils, mobilizes hematopoietic stem and progenitor cells (8, 9) , and modulates the differentiation, lifespan, and effector functions of mature neutrophils (10) (11) (12) (13) . G-CSF may also exert effects on macrophages, including expansion of monocyte͞macrophage numbers, enhancement of phagocytic function (14, 15) , and regulation of inflammatory cytokine and chemokine production (16, 17) . G-CSF is currently used to treat neutropenia and to mobilize hematopoietic stem cells for transplantation.
Administration of G-CSF can exacerbate RA (18) , murine collagen-induced arthritis (CIA) (19) and a passive transfer model of CIA in rats (20) . G-CSF has been found in the serum and synovial fluid of RA patients (21) . IL-1 and TNF induce the production of G-CSF by human synovial fibroblasts and chondrocytes in vitro (22, 23) . Transgenic mice expressing human G-CSF develop severe osteopenia (24) . This evidence indicates that G-CSF could be proinflammatory in inflammatory joint disease. However, administration of G-CSF also elicits regulatory CD4 ϩ T cells and dendritic cells (DC) that dampen allogeneic and mitogenic responses (25) (26) (27) . These effects of exogenous G-CSF have been correlated with reductions in murine graft vs. host disease (27) , experimental autoimmune encephalomyelitis (17) , and adjuvant arthritis in rats (28) .
We examined the absolute dependence of two models of inflammatory arthritis on endogenous G-CSF and evaluated whether endogenous G-CSF influences immune cell function. We show that G-CSF-deficient (G-CSF Ϫ/Ϫ ) mice are resistant to the induction of acute and chronic inflammatory arthritis. Furthermore, we demonstrate that G-CSF blockade in established CIA in WT mice markedly reduces the progression of disease. Protection against joint inflammation was associated with impaired granulopoiesis and reduced leukocyte trafficking and activation within inflamed joints. Examination of DC and T and B cell function failed to show abnormalities that would explain the marked protection of G-CSF Ϫ/Ϫ mice in these experimental models. Our results suggest that G-CSF drives inflammatory joint disease by increasing the production and mobilization of myeloid lineage cells from the bone marrow and inducing the trafficking and local activation of these cells in peripheral tissues. These data raise the possibility that G-CSF antagonists may be of therapeutic value in diseases such as RA. Peripheral Blood and Bone Marrow Leukocyte Counts. Retroorbital bleeds and bone marrow were analyzed on an Advia 120 automatic cell analyzer (Bayer Diagnostics, Tarrytown, NY). Bone marrow differential cell counts were performed manually on cytocentrifuged cells stained with May-Grünwald Giemsa.
Flow Cytometry. Synovial tissue was dissected from mouse knee joints and enzymatically dissociated as described (31) . Leukocytes were stained by using biotinylated and phycoerythrin-and FITC-conjugated Abs: anti-mouse CD45.2 (clone 104, BD Pharmingen), CD11b (Mac-1, clone M1͞70, Caltag, Burlingame, CA), GR-1 (clone RB6.8C5, American Type Culture Collection), CD44 (clone IM7, BD Pharmingen), and CD4 (clone CT-CD4, Caltag). Biotinylated Abs were detected with streptavidin-TriColor (Caltag). The level of nonspecific staining was determined by using irrelevant isotype-matched Abs. Cells were analyzed on a FACScan by using CELLQUEST software (Becton Dickinson).
CIA. CIA was induced as described (32) . Chick type II collagen (CII, 2 mg͞ml; Sigma) was dissolved in 10 mM acetic acid overnight at 4°C and emulsified in an equal volume of complete Freund's adjuvant (CFA), containing 5 mg͞ml heat-killed Mycobacterium tuberculosis H37RA (Difco). In specified experiments incomplete Freund's adjuvant was used. Mice were injected intradermally at the base of the tail with 100 l of the emulsion, and this was repeated 21 days later. Animals were regularly monitored blinded to experimental groups for erythema and swelling of limbs, and a clinical score (0-3) was given for each limb. At killing, paws of the four most clinically severe B6, plus affected and nonaffected G-CSF Ϫ/Ϫ mice, were processed for blinded histological assessment. Each paw provided more than seven joints for analyses, and each joint was graded from 0 to 3 in severity (33) .
Therapeutic administration of neutralizing mAb in CIA was performed as described (19) . WT DBA͞1 mice were immunized, and, once arthritis was clinically evident, mice were matched for initial disease severity and then randomly allocated to treatment with 250 g of rat anti-mouse G-CSF (clone 67604, R & D Systems), TNF (clone XT22), or isotype control (GL113, rat IgG1) mAb on days 1, 2, 3, 4, 5, 7, 9, and 12. A clinical score was given to each limb of arthritic mice every day for 14 days. Paws were also assessed histologically (Ն6 joints per paw). ) were isolated by negative selection as described (34) . DC phenotypic markers, examined by flow cytometry on purified naive DC, included CD11c (clone N4͞18), MHC II (clone M5͞114), MHC I (clone M1͞42), CD80 (B7-1, clone 16-10A1, BD Pharmingen), CD86 (B7-2, clone G1, BD Pharmingen), and CD11b. For OVApresentation experiments, mice were injected i.v. with whole OVA protein (3 mg per mouse; Sigma) or PBS vehicle. DC were isolated 16 h later, and 0-8 ϫ 10 4 irradiated (2,000 rad) DC were cultured with OVA-specific OT-II CD4 Total Ig-and CII-Specific Antibodies. Serum total IgG, IgM, IgG2c, IgG2b, IgG1, IgG3, and IgA were measured by using paired capture and HRP-conjugated Abs (Southern Biotechnology Associates). ELISAs for Abs to CII were performed as described (32) by using HRP-conjugated Ab to IgG (Sigma) and IgM, IgG2c, IgG2b, IgG1, and IgG3 (Southern Biotechnology Associates). 
CII-Specific Lymph
-sample rank test was used to compare clinical severity scores, histological scores, and anti-CII Ab levels. Student's t test for the difference of two means was used to analyze differential cell counts, proliferation assays, ELISAs, and flow cytometric analyses. P Ͻ 0.05 was considered statistically significant.
Results

G-CSF Deficiency
Reduces Acute Inflammatory Arthritis. IL-1 is a major mediator of RA (35) , and, when given systemically in mice, it transforms the weak inflammatory reaction to intraarticular mBSA into a florid monoarthritis. The severity of arthritis peaks on day 7 (36). We assessed the absolute requirement for endogenous G-CSF in acute mBSA͞IL-1-induced arthritis by using G-CSF Ϫ/Ϫ mice. Compared with B6 mice, G-CSF Ϫ/Ϫ mice had significantly reduced acute arthritis histological scores (Fig.  1a) , and marked protection against cartilage proteoglycan depletion ( Fig. 1 b and c) . Disease in G-CSF Ϫ/Ϫ mice was more comparable with the mild inflammatory reaction in B6 mice treated with mBSA alone (mBSA͞saline). These results demonstrate that IL-1-driven joint inflammation and destruction in this disease model is G-CSF-dependent.
Reduced Granulopoiesis and Joint Infiltration in G-CSF ؊/؊ Mice in
Response to IL-1. We next investigated the hematopoietic response during acute inflammatory arthritis. mBSA and IL-1 administration enhanced granulopoiesis and increased peripheral blood neutrophil numbers in B6 mice by day 7 (Table 1) . In contrast, G-CSF Ϫ/Ϫ mice displayed no rise in circulating neutrophil numbers, and blunted bone marrow production of myeloid lineage cells in response to IL-1 (Table 1) .
To determine whether G-CSF deficiency affected the composition of the infiltrating cells in the joint synovium, we dissociated synovial tissue and examined the expression of a range of hematopoietic markers on CD45 ϩ leukocytes. G-CSF Ϫ/Ϫ mBSA͞IL-1-treated mice had markedly less infiltrating CD45 ϩ leukocytes at day 7 compared with B6 mBSA͞IL-1-treated mice, and had similar numbers to B6 mBSA͞saline control mice (CD45 ϩ synovial leukocytes ϫ 10 (Fig. 1e) . Thus, as well as inhibiting IL-1-induced granulopoiesis, the absence of G-CSF also impaired neutrophil, monocyte͞macrophage, and CD4 ϩ T cell recruitment into the synovium and local activation of infiltrating leukocytes.
G-CSF ؊/؊ Mice Are Protected from Chronic Autoimmune Arthritis.
CIA is a chronic autoimmune polyarthritis and is the most widely used model of RA. We immunized B6 and G-CSF Ϫ/Ϫ mice for CIA as described (32) . The onset of CIA was slightly delayed in G-CSF Ϫ/Ϫ mice, and the cumulative incidence of disease was dramatically reduced (P Ͻ 0.001) compared with B6 mice (Fig.  2a) . In affected G-CSF Ϫ/Ϫ mice, clinical severity was much lower than in B6 mice (P Ͻ 0.0001) (Fig. 2b) , and joint swelling was restricted to single digits.
CIA can also be assessed histologically. From each of the three experiments performed, four of the most severely clinically affected B6 mice, plus clinically affected and nonaffected G-CSF Ϫ/Ϫ mice, were examined for histological features of CIA. G-CSF Ϫ/Ϫ mice had features of inflammatory arthritis in only 4% of joints, compared with 48% of B6 joints (P Ͻ 0.001). Of the small proportion of joints affected in G-CSF Ϫ/Ϫ mice, none was severely inflamed (Fig. 2 c and d) . G-CSF deficiency therefore affords marked protection against the clinical and histological features of CIA.
Cellular Responses in G-CSF ؊/؊ Mice. Induction of CIA depends on humoral and cellular immune responses to CII (32) , and acute mBSA͞IL-1-induced arthritis depends on CD4 ϩ T cells (31) . It was therefore important to carefully examine relevant immunological parameters in G-CSF Ϫ/Ϫ mice. There were no significant differences in draining LN T cell proliferative responses (Fig.  3a) , or in IFN-␥ or IL-2 production (Fig. 3b) to CII between CIA-immunized G-CSF Ϫ/Ϫ and B6 mice. Thus, defects in T cell function are unlikely to explain reduced CIA in G-CSF Ϫ/Ϫ mice.
Impaired Humoral Responses to CII and CFA in G-CSF ؊/؊ Mice. We first determined that basal Ig levels in naive G-CSF Ϫ/Ϫ mice were not reduced compared with naive B6 mice (data not shown). To examine B cell function in CIA, mice were bled for serum anti-CII-specific Abs at day 62 post-primary immunization. In comparison with B6 mice, G-CSF Ϫ/Ϫ mice had comparable levels of anti-CII IgM but had significantly reduced total anti-CII IgG and a generalized impairment of anti-CII IgG2b, IgG2c, IgG1, and IgG3 Ab production (Fig. 3c) . These results demonstrate a defect in isotype switching in G-CSF Ϫ/Ϫ mice under these immunization conditions. However, G-CSF Ϫ/Ϫ immunized with CII in incomplete Freund's adjuvant had equivalent anti-CII Ab In contrast, G-CSF Ϫ/Ϫ mice maintained a neutropenia throughout the course of CIA (neutrophils ϫ 10 Ϫ4 ͞ml blood Ϯ SEM in G-CSF Ϫ/Ϫ mice: day 0, 18 Ϯ 2 vs. day 30 of CIA, 30 Ϯ 5). Therefore, the autoimmune response that elicits CIA in peripheral tissues also acts on the bone marrow to promote granulopoiesis, and this response is mediated by G-CSF.
G-CSF Blockade Reduces the Progression of Established CIA.
In view of the protection from acute and chronic inflammatory arthritis in G-CSF Ϫ/Ϫ mice, we posed the most clinically relevant question: does G-CSF blockade have therapeutic potential in established CIA? For therapeutic studies, DBA͞1 mice (the most CIA-responsive strain) were immunized with CII in CFA and boosted at day 21. Mice were examined clinically from day 21 and, at the onset of arthritis, were matched for initial disease severity and then randomly allocated to treatment with isotype control, anti-G-CSF, or anti-TNF mAb. Inhibition of G-CSF impaired disease progression and reduced clinical severity compared with control mAb-treated mice (Fig. 4a) . Anti-G-CSF mAb treatment also reduced peripheral blood neutrophils (percentage of metamyelocytes͞neutrophils in peripheral blood at day 14: control mAb 41%; anti-G-CSF mAb 13%; anti-TNF mAb 42%). Importantly, the beneficial clinical response to anti-G-CSF mAb was comparable to anti-TNF mAb (mean clinical score Ϯ SEM over 14 days of arthritis: control mAb 5.4 Ϯ 0.8; anti-G-CSF mAb 2.5 Ϯ 0.5, P Ͻ 0.01; anti-TNF mAb 3.3 Ϯ 0.9, P Ͻ 0.05). Histological examination of paws confirmed a reduction in the number (percentage of arthritic joints: control mAb 54%; anti-G-CSF mAb 23%, P Ͻ 0.001; anti-TNF mAb 22%, P Ͻ 0.001) and disease severity of affected joints (Fig. 4b) . Anti-G-CSF mAb did not significantly alter the serum levels of anti-CII IgM or anti-CII IgG Abs (data not shown). Inhibition of G-CSF in established CIA therefore blocks the progression of inflammatory joint disease.
Discussion
We demonstrate that endogenous G-CSF is a critical mediator of acute and chronic inflammatory arthritis in mice and that inhibition of endogenous G-CSF in established autoimmune inflammatory arthritis reduces the progression and severity of disease. Our studies raise the following questions: why are mice lacking endogenous G-CSF protected from acute and chronic arthritis and how does anti-G-CSF mAb therapy impair the progression of CIA in WT mice? In both the acute and chronic arthritis models, we observed reduced production and mobilization of granulocytic cells from the bone marrow to the blood, and there was reduced myeloid cell activation in the joint infiltrate of G-CSF Ϫ/Ϫ mice with acute arthritis. Thus, we hypothesize that antagonizing G-CSF impairs myelopoiesis, thereby reducing the supply of inflammatory cells available to contribute to joint inflammation. The reduction in inflammatory cells in the acute IL-1-dependent arthritis model was associated with marked protection against cartilage proteoglycan depletion, highlighting the potential role of G-CSF-induced leukocyte recruitment and activation in mediating cartilage damage. Collectively, these data are consistent with the idea that G-CSFregulated myeloid lineage cells are crucial effector cells in the expression of acute and chronic inflammatory joint disease.
The reduced inflammatory cell infiltrate and lower expression of CD44 in the absence of G-CSF also raise the possibility of local proinflammatory effects for G-CSF. CD44 is a leukocyte activation marker and adhesion receptor for hyaluronan, which may contribute to leukocyte migration within the synovium (37). G-CSF has been shown to activate endothelial cells (38) , modulate the expression of leukocyte adhesion molecules (39, 40) , and enhance angiogenesis (41) , and may induce chemokine production (39) . G-CSF also enhances neutrophil and macrophage phagocytosis (14, 15) and prolongs neutrophil survival (12) . Local tissue production of G-CSF might therefore mediate adhesion and trafficking of myeloid cells through the endothelium, as well as promote local cellular activation, function, and survival within inflamed tissues.
Administration of G-CSF can induce a shift from Th1 to Th2 cytokine production (27) , mobilize type 2 regulatory DC (26) , and dampen mitogenic and allogenic responses in T cells (25, 27) . G-CSF can also induce Ig production from human B cells (42) . It was therefore important to examine immune parameters in G-CSF Ϫ/Ϫ mice. We demonstrate normal CD4 ϩ T cell and DC responses in G-CSF Ϫ/Ϫ mice. Although reduced anti-CII Ab isotype switching in G-CSF Ϫ/Ϫ mice could partly explain reduced CIA, TNF-deficient mice had an even greater impairment in anti-CII isotype switching but could still develop severe CIA (33) . The acute mBSA͞IL-1 arthritis model is also B cell independent (31) . Furthermore, therapeutic administration of anti-G-CSF mAb to WT mice ameliorated CIA but did not depress the anti-CII Ab response.
Our observations provide a rationale for the development of G-CSF antagonists for the treatment of RA. However, although we know a great deal about the effects of administering G-CSF, what might be the downside of inhibiting endogenous G-CSF? On the whole, cytokine antagonists have been remarkably well tolerated in RA but clearly increase the risk of infection (43) . Importantly, we have shown that the adaptive immune response in G-CSF Ϫ/Ϫ mice seems to be relatively intact, apart from a 
